Circulating CD33+ cells, CD33+HLA-DR−, or CD33+HLA-DR−Lin− are described to be MDSCs in patients with renal cell cancer, colorectal cancer, or hepatocellular carcinoma, respectively [16–18]. This evidence concerns the gene CD33 and renal cell adenocarcinoma.